Catalyst Wire Dossier Catalyst Wire Dossier

CVL237

· Convalife (Shanghai) Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CVL237, covering 2026-03-03 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression [Phase 2]

See pricing